Gain Therapeutics (GANX) Non-Current Debt (2020 - 2026)
Gain Therapeutics (GANX) posted quarterly Non-Current Debt of $273265.0 for Q1 2026, down 13.1% year-over-year from $314476.0 in Q1 2025, and down 8.94% quarter-over-quarter from $300084.0 in Q4 2025.
Gain Therapeutics (GANX) Non-Current Debt (2020 - 2026) Analysis & Trends
Gain Therapeutics' Non-Current Debt history runs 7 years deep, the most recent figure standing at $273265.0 for Q1 2026.
- In Q1 2026, Non-Current Debt fell 13.1% year-over-year to $273265.0; the TTM figure through Mar 2026 stood at $273265.0 (down 13.1% YoY), while the FY2025 annual figure was $300084.0, down 8.6% from the prior year.
- Non-Current Debt for Q1 2026 stood at $273265.0, down from $300084.0 in the prior quarter.
- The five-year high for Non-Current Debt was $560889.0 in Q1 2022, with the low at $273265.0 in Q1 2026.
- The 5-year median for Non-Current Debt is $396836.0 (2024), against an average of $405881.4.
- The sharpest annual moves came in 2024 and 2025: Non-Current Debt dropped 26.88% in 2024, then declined 8.6% in 2025.
- Gain Therapeutics' Non-Current Debt stood at $495258.0 in 2022, then decreased by 9.33% to $449053.0 in 2023, then retreated by 26.88% to $328327.0 in 2024, then slipped by 8.6% to $300084.0 in 2025, then dropped by 8.94% to $273265.0 in 2026.
- Business Quant data shows GANX's Non-Current Debt at $273265.0 in Q1 2026, $300084.0 in Q4 2025, and $298797.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Debt (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 1.99 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 591.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 882.16 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | - |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 360.97 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 546.77 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 8.96 Bn |
| 10 | Gain Therapeutics | 85.97 Mn | 85.97 Mn | - | 220,058.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 220,058.00 |
| Mar 31, 2026 | 273,265.00 |
| Dec 31, 2025 | 300,084.00 |
| Sep 30, 2025 | 298,797.00 |
| Jun 30, 2025 | 325,359.00 |
| Mar 31, 2025 | 314,476.00 |
| Dec 31, 2024 | 328,327.00 |
| Sep 30, 2024 | 376,130.00 |
| Jun 30, 2024 | 375,352.00 |
| Mar 31, 2024 | 396,836.00 |
| Dec 31, 2023 | 449,053.00 |
| Sep 30, 2023 | 434,938.00 |
| Jun 30, 2023 | 466,638.00 |
| Mar 31, 2023 | 478,296.00 |
| Dec 31, 2022 | 495,258.00 |
| Sep 30, 2022 | 484,023.00 |
| Jun 30, 2022 | 542,263.00 |
| Mar 31, 2022 | 560,889.00 |
| Dec 31, 2021 | 590,468.00 |
| Sep 30, 2021 | 620,167.00 |